[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582973":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":19,"responsibleParty":26,"collaborators":19,"id":28,"slug":19,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":19,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":35,"maxAge":36,"enrollmentInfo":37,"targetDuration":19,"studyType":40,"phases":41,"briefSummary":43,"conditions":44,"keywords":19,"overallStatus":46,"whyStopped":19,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":19},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CAR-NKT Cells Lymphodepleting regimen","EXPERIMENTAL","CAR-NKT Cells treatment",[13],"Drug: CGC738",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","CGC738",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Zhai Wei","CONTACT","+8618701771959","jackyzw2007@163.com",{"type":27,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100582973",false,"NCT06870279","A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC","A Clinical Research Evaluating the Safety and Efficacy of CD70-targeted CAR-NKT Cells (CGC738) Therapy in Subjects With Advanced Clear Cell Renal Cell Carcinoma","Inclusion Criteria:\n\n* 1\\. Age 18 to 75 years.\n* 2.ECOG 0-1 points.\n* 3\\. The expected survival time is more than 3 months.\n* 4\\. Patients with advanced ccRCC confirmed by histology or cytology to be recurrent or metastatic after at least first-line treatment.\n* 5\\. IHC: CD70 positive.\n* 6\\. At least one measurable lesion at baseline per RECIST version 1.1.\n* 7\\. The functions of important organs are basically normal:\n* 8\\. Pregnancy tests for women of childbearing age shall be negative, both men and women agreed to use effective contraception.\n\nExclusion Criteria:\n\n* 1\\. Use of cell therapy within the previous one month.\n* 2\\. Subjects with other malignant tumors within the past 2 years, except basal or squamous skin cancer, superficial bladder cancer, and breast cancer in situ, have been completely cured and do not need follow-up treatment.\n* 3\\. Patients with leptomeningeal metastasis or central nervous system metastasis, and definite central nervous system underlying diseases with significant symptoms.\n* 4\\. Immunotherapy, targeted drug therapy or chemotherapy within 5 drug half-lives within 2 weeks before cell infusion.\n* 5\\. Active hepatitis B, HIV positive and HCV positive.\n* 6\\. Active infection or uncontrollable infection.\n* 7\\. Uncontrollable or significant heart disease.\n* 8\\. Unstable respiratory diseases, including interstitial pneumonia.\n* 9\\. Uncontrolled ascites and pleural effusion.\n* 10.Known to have active or uncontrolled autoimmune diseases, such as Crohns disease, rheumatoid arthritis, systemic lupus erythematosus, etc.\n* 11.Subjects who are using systemic steroids or steroid inhalers for treatment.\n* 12.Pregnant or lactating female subjects.\n* 13.Other investigators deem it unsuitable to participate in the study","ALL","18 Years","75 Years",{"count":38,"type":39},28,"ESTIMATED","INTERVENTIONAL",[42],"PHASE1","This is a phase I, open-label, single-arm study conducted to evaluate the efficacy, safety and PK of CGC738 in the treatment of advanced clear cell renal cell carcinoma (ccRCC).",[45],"Advanced Clear Cell Renal Cell Carcinoma","NOT_YET_RECRUITING","2025-04-19",{"date":49,"type":50},"2025-04-24","ACTUAL",{"date":52,"type":39},"2025-05-25",{"date":54,"type":39},"2026-12-31",{"name":5,"class":6}]